业 研 究 行 行业周报 Optimus 3 发布在即，关注近期事件催化 | | | | | ——机械设备行业周报 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 分析师： | 宁前羽 | SAC NO： | S1150522070001 | 2026 | 年 1 月 | 28 | 日 | | 机械设备 | | | | | | | | | | | 投资要点： | | | | | | | 证券分析师 | | | | | | | | | 宁前羽 | |  行业要闻 | | | | | | | ningqy@bhzq.com | | （1）2025 年 12 | 月份塔机台天利用率 55.1%。 | | | | | | 022-23839174 | | | | | | | | | | | （2）2025 | 年全国规模以上工业企业利润增长 0.6%。 | | | | | | | | 公司公告  | | | | | | | 重点品种推荐 | | | | | | | | | 中联重科 | 增持 | （1）捷昌驱动发布 | 2025 年年度业绩预 ...

Investment Rating - The report assigns an "Accumulate" rating for the robotics industry [4]. Core Insights - The report highlights the deepening strategies of overseas giants, with OpenAI entering the robotics field and the acceleration of embodied intelligence in Europe. In China, new products and operational scenarios are flourishing, with breakthroughs in both production scale and data elements. The investment and financing market is robust, leading to an expansion of the robotics supply chain and production capacity [2][3]. Summary by Sections Industry News and Company Dynamics - Optimus is already operational in factories and is expected to begin consumer sales by the end of 2027. CEO Elon Musk confirmed this timeline at the World Economic Forum in Davos, stating that several units are currently performing simple tasks and will be ready for more complex operations soon [6][7]. - Yushutech announced that it exceeded 5,500 units in actual sales of humanoid robots for 2025, with over 6,500 units produced. The company clarified that this figure refers to actual sales delivered to end customers [7]. - Shanghai Jiao Tong University and Jieke Robotics have established a joint research center focused on general intelligent robots, aiming for breakthroughs in core technologies and industrial applications [7]. Investment and Financing Dynamics - The financing demand in the robotics sector is increasing, with Skild AI raising approximately $1.4 billion in funding led by SoftBank and NVIDIA, focusing on developing a general robotic "brain" [9]. - Zhejiang Human Robot Innovation Center completed a Pre-A round financing of 450 million yuan, with a strong lineup of investors, aimed at advancing core technologies and scaling production [9]. - Huari Technology plans to go public in Hong Kong, focusing on machine vision and autonomous mobile robots [9]. Investment Recommendations - The report recommends focusing on both complete robotics manufacturers and core component suppliers. Key recommendations include: 1. Actuators and motors: Recommended companies include Zhaowei Electromechanical, with related companies being Mingzhi Electric and Jiechang Drive. 2. Reducers: Related companies include Ruidi Zhichu and Haoneng Co. 3. Screw components: Recommended company is Hengli Hydraulic, with related companies being Zhejiang Rongtai and Best. 4. Screw equipment: Recommended company is Qin Chuan Machine Tool, with related companies being Rifa Precision and Huachen Equipment. 5. Bearings: Recommended company is Longxi Co. 6. Sensors: Recommended companies include Donghua Testing and Anpeilong, with related companies being Lingyun Co. 7. Complete machines: Related companies include Ubtech and Yijiahe [10][12].

格隆汇1月23日｜东吴证券研报指出，捷昌驱动25年业绩预告超市场预期，机器人零部件深化布局。公 司作为线性驱动行业龙头，在全球多地设有子公司并设立了宁波、新昌、马来西亚、美国、欧洲5大生 产基地，25年欧洲物流及生产基地一期基本建设完毕，将与德国子公司及奥地利LOGICDATA形成深度 协同，进一步提升公司在欧洲地区技术研发、生产交付及供应链管理能力。此外，通过构建高效的客户 需求快速响应机制，公司有效提升客户满意度和粘性，进而提升市占率，实现线性驱控业务稳健增长。 展望26年，预计公司线性驱动业务收入有望保持同比20-30%的稳健增长。公司深度自研构建机器人零 部件产品线，打造第二增长曲线。考虑到公司海外布局持续深化，业绩稳健增长，上修公司25-27年预 测归母净利润分别为4.16/5.45/7.12亿元（此前预测3.92/4.97/6.40亿元），同比+47%/31%/31%，现价对 应PE分别为36x、27x、21x，维持"买入"评级。 ...

证券研究报告·公司点评报告·自动化设备 捷昌驱动（603583） 2025 年业绩预告点评：业绩超市场预期，机 器人零部件深化布局 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,034 | 3,652 | 4,424 | 5,319 | 6,387 | | 同比（%） | 0.91 | 20.37 | 21.13 | 20.25 | 20.07 | | 归母净利润（百万元） | 205.96 | 281.98 | 415.75 | 544.90 | 711.69 | | 同比（%） | (37.16) | 36.91 | 47.44 | 31.07 | 30.61 | | EPS-最新摊薄（元/股） | 0.53 | 0.73 | 1.08 | 1.41 | 1.84 | | P/E（现价&最新摊薄） | 72.09 | 52.66 | 35.71 | 27.25 | 20.86 | [Table_Tag] ...

捷昌驱动（603583） 证券研究报告·公司点评报告·自动化设备 2025 年业绩预告点评：业绩超市场预期，机 器人零部件深化布局 2026 年 01 月 23 日 证券分析师 曾朵红 执业证书：S0600516080001 021-60199793 zengdh@dwzq.com.cn 证券分析师 许钧赫 买入（维持） 执业证书：S0600525090005 xujunhe@dwzq.com.cn | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,034 | 3,652 | 4,424 | 5,319 | 6,387 | | 同比（%） | 0.91 | 20.37 | 21.13 | 20.25 | 20.07 | | 归母净利润（百万元） | 205.96 | 281.98 | 415.75 | 544.90 | 711.69 | | 同比（%） | (37.16) | 36.91 | 47.44 | 31.07 | ...

证券研究报告·公司点评报告·自动化设备 捷昌驱动（603583） 2025 年业绩预告点评：业绩超市场预期，机 器人零部件深化布局 买入（维持） 2026 年 01 月 23 日 证券分析师 曾朵红 执业证书：S0600516080001 021-60199793 zengdh@dwzq.com.cn 市场数据 证券分析师 许钧赫 执业证书：S0600525090005 xujunhe@dwzq.com.cn 股价走势 -6% 3% 12% 21% 30% 39% 48% 57% 66% 75% 84% 2025/1/23 2025/5/24 2025/9/22 2026/1/21 捷昌驱动 沪深300 | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,034 | 3,652 | 4,424 | 5,319 | 6,387 | | 同比（%） | 0.91 | 20.37 | 21.13 | 20.25 | 20.07 | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 （二）业绩预告情况 经财务部门初步测算，预计2025年年度实现归属于上市公司股东的净利润39,476.74万元至43,706.39万 元，与上年同期相比，将增加11,279.07万元至15,508.72万元，同比增长40.00%至55.00%。 ● 预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润36,481.50万元至40,711.15万 元，与上年同期相比，将增加12,341.48万元至16,571.13万元，同比增长51.12%至68.65%。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润36,481.50万元至40,711.15万元， 与上年同期相比，将增加12,341.48万元至16,571.13万元，同比增长51.12%至68.65%。 重要内容提示： ● 业绩预告具体适用于实现盈利，且净利润与上年同期相比增长50%以上的情形。 ● 浙江捷昌 ...

深南电A：2025年净利润同比预增584.66%-721.59% 特一药业：2025年净利润同比预增241.55%-339.13% 闰土股份：2025年净利润同比预增181.05%-227.89% 青松股份：2025年净利润同比预增137.73%-201.74% 瑞晟智能：2025年净利润同比预增112.00%-139.99% 键凯科技：2025年净利润同比预增101.09%-121.20% 兴齐眼药：2025年净利润同比预增95.82%-121.56% 睿创微纳：2025年净利润同比预增93%左右 天禾股份：2025年净利润同比预增84.35%-169.78% 中元股份：2025年净利润同比预增80%-105% 亿道信息：2025年净利润同比预增76.04%-128.85% 圣达生物：2025年净利润同比预增69.93%-120.90% 华锐精密：2025年净利润同比预增68.29%-86.99% 方正科技：2025年净利润同比预增67.06%-98.14% 金陵饭店：2025年净利润同比预增65.37%-90.93% 强一股份：2025年净利润同比预增57.87%-71.17% 朗博科技：2025年净利润 ...

（文章来源：证券日报） 证券日报网讯 1月22日，捷昌驱动发布公告称，公司预计2025年年度实现归属于上市公司股东的净利润 39，476.74万元至43，706.39万元，与上年同期相比，将增加11，279.07万元至15，508.72万元，同比增 长40.00%至55.00%。 ...

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]